{"product_id":"recombinant-human-insulin-receptor-insr-partial-bhp10504743","title":"Recombinant Human Insulin receptor (INSR), partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eRecombinant Human Insulin receptor (INSR), partial is a recombinant protein reagent for research-use applications such as assay development, binding studies, and mechanistic experiments. It corresponds to \u003cstrong\u003eINSR\u003c\/strong\u003e (Homo sapiens (Human)) and is intended for RUO workflows where a defined protein standard or functional input is needed.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli (expression context can influence folding and PTMs).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e 1023-1298aa (region choice can affect activity and binding readouts).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConjugate(s)\/tag:\u003c\/strong\u003e N-terminal 6xHis-SUMO-tagged (can support detection or purification depending on format).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 47.2 kDa (useful for interpreting gel migration and size-exclusion profiles).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eWhen comparing results across assays, consider that expression system and expressed region can alter glycosylation, disulfide formation, and oligomerization state, which may shift apparent potency or binding behavior in vitro.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eReceptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT\/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine\/threonine kinases, such as PDPK1 and subsequently AKT\/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4\/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT\/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT\/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras\/RAF\/MAP2K\/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2\/SOS complex, which triggers the activation of the Ras\/RAF\/MAP2K\/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eReagent standardization: using recombinant proteins as reference materials for quantitative calibration and cross-study comparability.\u003c\/li\u003e\n\u003cli\u003eInteraction-focused studies: mapping binding partners, affinity changes, and structure–function relationships across variants or domains.\u003c\/li\u003e\n\u003cli\u003eMulti-omic readouts: combining recombinant perturbations with transcript, protein, and functional endpoints to connect mechanism to phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAssay development and validation: use as a defined input or standard where protein identity is required.\u003c\/li\u003e\n\u003cli\u003eBinding studies: evaluate interaction strength and specificity using plate-based or biophysical formats.\u003c\/li\u003e\n\u003cli\u003eCell-response profiling: add protein to cultured cells and interpret downstream marker changes with appropriate controls.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation is most robust when signal changes are evaluated relative to matched controls (buffer-only, unrelated protein controls, or pathway controls) and when readouts are compared across dose and time.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIsoforms and PTMs can influence binding and activity; ensure the expressed region and expression system match your experimental needs.\u003c\/li\u003e\n\u003cli\u003eSpecies differences may affect receptor binding or antibody recognition; confirm species\/source alignment with your model.\u003c\/li\u003e\n\u003cli\u003eUse concept-level controls such as negative controls (no protein), matrix controls, or orthogonal readouts to support conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt keyword search: https:\/\/www.uniprot.org\/uniprotkb?query=INSR - NCBI Gene search: https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=INSR - PubMed search: https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=INSR - Ensembl search: https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=INSR - Reactome Pathway Browser: https:\/\/reactome.org\/content\/query?q=INSR --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53053065232749,"sku":"CSB-EP011753HU-1MG","price":1812.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53053229990253,"sku":"CSB-EP011753HU-100UG","price":419.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53053230023021,"sku":"CSB-EP011753HU-20UG","price":224.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP011753HU-SDS.jpg?v=1772172945","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-insulin-receptor-insr-partial-bhp10504743","provider":"BioHippo","version":"1.0","type":"link"}